VTEU 13-0053 Task Area C: Phase I, single dose, open-label, parallel group study comparing the pharmacokinetics and safety of PA-824 in subjects with mild, moderate, and severe hepatic impairment to matched, normal, healthy subjects.

Administered By

Awarded By

Contributors

Start/End

  • September 11, 2014 - October 31, 2020